BR112012000209B8 - heterodímeros de ácido glutâmico e seus processos de preparação - Google Patents

heterodímeros de ácido glutâmico e seus processos de preparação

Info

Publication number
BR112012000209B8
BR112012000209B8 BR112012000209A BR112012000209A BR112012000209B8 BR 112012000209 B8 BR112012000209 B8 BR 112012000209B8 BR 112012000209 A BR112012000209 A BR 112012000209A BR 112012000209 A BR112012000209 A BR 112012000209A BR 112012000209 B8 BR112012000209 B8 BR 112012000209B8
Authority
BR
Brazil
Prior art keywords
heterodimers
glutamic acid
preparation processes
formula
benzyl
Prior art date
Application number
BR112012000209A
Other languages
English (en)
Other versions
BR112012000209B1 (pt
BR112012000209A2 (pt
Inventor
zimmermann Craig
W Babich John
P Maresca Kevin
Original Assignee
Molecular Insight Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Insight Pharm Inc filed Critical Molecular Insight Pharm Inc
Publication of BR112012000209A2 publication Critical patent/BR112012000209A2/pt
Publication of BR112012000209B1 publication Critical patent/BR112012000209B1/pt
Publication of BR112012000209B8 publication Critical patent/BR112012000209B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1854—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

heterodímeros de ácido glutâmico e seus processos de preparação. um processo de fabricação para a preparação de compostos radiorrotulados de fórmula (i) (i), inclui a reação de compostos de fórmula (ii) com uma fonte de radionucleotídeo de um halogênio na presença de um oxidante sob condição acídica, (ii) em que: *l é 123l, 124l, 125l ou 131l; r é alquila inferior, opcionalmente substituída com um ou mais átomos de flúor; q é c(o), o, nr', s, s(o)2, c(o)2, (ch2)p; y é c(o), o, nr', s, s(o)2, c(o)2, (ch2)p; r' é h, c(o), s(o)2, c(o)2; z é h, c1-c4 alquila, benzila, benzila substituída ou trialquilsilila; m é 0, 1, 2, 3, 4 ou 5; n é 0, 1, 2, 3, 4, 5 ou 6; e p é 0, 1, 2, 3, 4, 5 ou 6.
BR112012000209A 2009-06-15 2010-06-15 heterodímeros de ácido glutâmico e seus processos de preparação BR112012000209B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18712009P 2009-06-15 2009-06-15
US61/187,120 2009-06-15
PCT/US2010/038645 WO2010147965A2 (en) 2009-06-15 2010-06-15 Process for production of heterodimers of glutamic acid

Publications (3)

Publication Number Publication Date
BR112012000209A2 BR112012000209A2 (pt) 2017-07-11
BR112012000209B1 BR112012000209B1 (pt) 2020-10-13
BR112012000209B8 true BR112012000209B8 (pt) 2021-07-27

Family

ID=43067201

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012000209A BR112012000209B8 (pt) 2009-06-15 2010-06-15 heterodímeros de ácido glutâmico e seus processos de preparação
BR112012000210A BR112012000210A2 (pt) 2009-06-15 2010-06-15 processo para a produção de heterodímeoros de ácido glutâmico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112012000210A BR112012000210A2 (pt) 2009-06-15 2010-06-15 processo para a produção de heterodímeoros de ácido glutâmico.

Country Status (4)

Country Link
US (2) US8465725B2 (pt)
AU (1) AU2010260195B2 (pt)
BR (2) BR112012000209B8 (pt)
WO (1) WO2010147965A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528499B1 (en) * 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
CA2669127C (en) 2006-11-08 2016-09-13 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
AU2013344778C1 (en) 2012-11-15 2024-06-27 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
JP6908964B2 (ja) 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
CN105849568B (zh) 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
US20150147339A1 (en) 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
US9956305B2 (en) 2014-09-08 2018-05-01 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
JP7604397B2 (ja) 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Ｐｓｍａコンジュゲートの調製方法
CN111072653A (zh) * 2019-12-26 2020-04-28 浙江工业大学 一种由取代2-芳基吲哚嗪直接合成1,3-双硫代吲哚嗪类化合物的方法
WO2021202376A1 (en) 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
WO2025250655A1 (en) * 2024-05-29 2025-12-04 Cornell University Preparation of radiohalogenated compounds for nuclear medicine by reductive elimination from bismuth(v) halides

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US2730456A (en) 1953-06-30 1956-01-10 Ncr Co Manifold record material
US2730457A (en) 1953-06-30 1956-01-10 Ncr Co Pressure responsive record materials
US3527789A (en) 1967-10-06 1970-09-08 Shell Oil Co Production of poly(lower)alkyl alkenepolycarboxylates
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS6131056A (ja) 1984-07-25 1986-02-13 K Baiorojikaru Sci Lab:Kk ホイッピングクリームの製造方法
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
JP2608550B2 (ja) 1986-10-17 1997-05-07 株式会社 片山化学工業研究所 軟水ボイラの防食処理方法
US4888136A (en) 1988-05-02 1989-12-19 Witco Corporation New flame retardant compositions of matter and cellulosic products containing same
TW353663B (en) 1991-04-06 1999-03-01 Hoechst Ag Process for the preparation of phosphorus-containing L-amino acids, their derivatives and intermediates for this process
JP3051497B2 (ja) 1991-05-17 2000-06-12 株式会社第一ラジオアイソトープ研究所 スルファニルアミド誘導体のテクネチウム錯体をもちいる放射性診断剤
US6359120B1 (en) 1991-10-29 2002-03-19 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia-localizing moiety
NZ244613A (en) 1991-10-29 1996-05-28 Bracco International B V Subst A ligand containing a hypoxia-localising moiety, preparation thereof; a kit (optionally multivial) for preparing a metal complex containing the ligand
IT1270260B (it) 1994-06-21 1997-04-29 Zambon Spa Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
JP2856098B2 (ja) 1995-04-11 1999-02-10 日本製紙株式会社 感熱記録シート
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6071965A (en) 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
ATE229945T1 (de) 1998-03-19 2003-01-15 Upjohn Co Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US6479470B1 (en) 1999-04-28 2002-11-12 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase
US6228888B1 (en) 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
WO2002094261A1 (fr) 2001-05-24 2002-11-28 Kureha Chemical Industry Company, Limited Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
WO2003053932A1 (en) 2001-12-21 2003-07-03 Tohru Koike Zinc complexes capable of scavenging substances bearing anionic substituents
ATE443260T1 (de) 2002-01-10 2009-10-15 Univ Johns Hopkins Kontrastmittel und verfahren zum imaging von naaldase oder psma
WO2003077727A2 (en) 2002-03-11 2003-09-25 Biostream, Inc. Technetium-dipyridine complexes, and methods of use thereof
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
AU2003295950B2 (en) 2002-11-26 2007-06-28 Institute Of Virology CA IX-specific inhibitors
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7682601B2 (en) 2003-04-15 2010-03-23 Mallinckrodt Inc. Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes
CA2547863A1 (en) 2003-12-12 2005-06-23 Oy Juvantia Pharma Ltd Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
EP1718342A4 (en) 2004-02-12 2009-07-22 Molecular Insight Pharm Inc TECHNETIUM AND RHENIUM-BIS (HETEROARYL) COMPLEXES AND APPLICATION METHODS
GB0421308D0 (en) 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
WO2008059489A2 (en) 2006-11-13 2008-05-22 Spectrum Dynamics Llc Radioimaging applications of and novel formulations of teboroxime
WO2006080993A1 (en) 2004-12-08 2006-08-03 Purdue Research Foundation Novel cationic metal complex radiopharmaceuticals
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
WO2006116736A2 (en) 2005-04-27 2006-11-02 Siemens Medical Solutions Usa, Inc. A method for the preparation of imaging probes using click chemistry
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
FR2890657B1 (fr) 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
BRPI0621307A2 (pt) 2006-02-06 2011-12-06 Ciba Holding Inc. uso de compostos de complexo metálico como catalisadores de oxidação
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
ZA200810739B (en) 2006-06-20 2010-03-31 Ishihara Sangyo Kaisha Pesticide containing novel pyridyl-methanamine derivative or its salt
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
JP2010502646A (ja) 2006-08-29 2010-01-28 バイオストリーム セラピューティクス インコーポレーティッド ペプチダーゼ結合部分と結合しペプチダーゼ発現組織及び器官をイメージングする放射性イメージング部分
CA2669127C (en) 2006-11-08 2016-09-13 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
CA2683434A1 (en) 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
AU2009204133B2 (en) 2008-01-09 2014-04-10 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
EP2349995A1 (en) 2008-09-25 2011-08-03 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
BRPI0922839A2 (pt) 2008-12-05 2019-09-03 Molecular Insight Pharmaceuticals, Inc. radiofarmacêuticos específicos de ca-ix para tratamento e imageamento de câncer.
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer

Also Published As

Publication number Publication date
US20110008253A1 (en) 2011-01-13
WO2010147965A3 (en) 2011-07-28
WO2010147965A2 (en) 2010-12-23
US9149547B2 (en) 2015-10-06
BR112012000209B1 (pt) 2020-10-13
AU2010260195A1 (en) 2012-01-19
US8465725B2 (en) 2013-06-18
BR112012000209A2 (pt) 2017-07-11
US20140030188A1 (en) 2014-01-30
BR112012000210A2 (pt) 2019-09-24
AU2010260195B2 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
CY1113131T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
WO2010147965A3 (en) Process for production of heterodimers of glutamic acid
BRPI0814153B8 (pt) Método para preparar derivados de 5-haloalquil-4,5-diidroisoxazol e compostos de partida úteis no método
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
BR112014026703A2 (pt) inibidores de dna-pk
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
BR112012024117A2 (pt) inibidores de pirrolopirazina quinase
BRPI0514125A (pt) piridinas condensadas como inibidores de cinase
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
PE20120495A1 (es) 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas
CR20140057A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-etoxi-etil}-1h-[1,2,4]triazol sustituidos
BRPI0713190B1 (pt) composto e métodos para preparar compostos
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
EA201000484A1 (ru) Тиенопиримидиновые и пиразолопиримидиновые соединения и их применение в качестве ингибиторов киназы mtor и киназы pi3
BR122020014853B8 (pt) Éter, e, método de produção de um éter
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
NI201500134A (es) Derivados de 2-((4-amino-3-(3-flúor-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il) metil)-3-(2-(trifluorometil)bencil)quinazolina-4(3h)-ona y su uso como inhibidores de fosfoinositida 3-quinasas
BR112012032251A2 (pt) processo para a preparação de derivados da 2, 2-difluoroetilamina pela alquilação com 2,2 difluoroetil-1-haloetanos
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
PE20151754A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]
B151 Others concerning applications: resolution cancelled [chapter 15.31 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO